Last updated: 2026-10-19 23:21:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Biohaven Ltd. (BHVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $11.36, with a market capitalization of $1.63B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.48 to $18.57. This page covers its latest market performance, valuation, price trends and company information.
$1.63B | |
$11.01 | |
$152.56 | |
$7.10 | |
$10.78 | |
1.36M | |
2.63M | |
-- | |
$18.57 | |
$7.48 | |
-- | |
-- |
Biohaven Ltd. (BHVN) is trading at $11.22 in after-hours trading as of 2026-10-19 23:00:00, up 4.08% ($0.44) from the regular-session close of $10.78.
After-hours trading shows how investors are pricing BHVN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Biohaven Ltd. (BHVN) moved from $11.93 to $11.36, representing a decline of 4.79% ($0.57).
The stock traded between $10.47 and $12.27 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.97 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35.0%
BHVN is currently trading at $11.36, placing it 35.0% of the way from its 52-week low of $7.48 to its 52-week high of $18.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 274 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Biohaven Ltd. (BHVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.